Related Experiment Videos

Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with

Takeshi Takami1, Minori Shigematsu

  • 1Clinic Jingumae, Kashihara, Nara, Japan. takami66@maple.ocn.ne.jp

Insights

Amlodipine and cilnidipine improved left ventricular hypertrophy and diastolic function in hypertensive patients, unlike nifedipine CR. N-type calcium channel blockade contributes to these beneficial effects.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • Hypertension commonly causes left ventricular (LV) hypertrophy and diastolic dysfunction.
  • Antihypertensive effects on LV structure/function may depend on mechanisms beyond blood pressure reduction, such as sympathetic nervous system and renin-angiotensin system modulation.

Purpose of the Study:

  • To investigate the effects of amlodipine and cilnidipine, calcium channel antagonists with differing N-type channel blockade, on LV hypertrophy and diastolic function in patients with essential hypertension.
  • To compare these effects with nifedipine CR, which lacks N-type channel blockade.

Main Methods:

  • Randomized controlled trial involving patients with essential hypertension assigned to amlodipine, cilnidipine, or nifedipine CR for 6 months.
  • Left ventricular mass index assessed by M-mode echocardiography.
  • Diastolic function evaluated using E/A ratio and E wave deceleration time via pulse Doppler echocardiography.

Main Results:

  • All three drugs significantly reduced blood pressure without intergroup differences.
  • Significant reductions in LV mass index were observed by 3 months with cilnidipine and 6 months with amlodipine, but not nifedipine CR.
  • Cilnidipine and amlodipine significantly improved diastolic function (decreased deceleration time, increased E/A ratio) after 3 months, while nifedipine CR did not.

Conclusions:

  • Long-acting calcium channel antagonists exhibit varied effects on hypertensive left ventricular hypertrophy and diastolic function.
  • Amlodipine and cilnidipine improved LV structure and function, whereas nifedipine CR did not.
  • Suppression of sympathetic nerve activity via N-type calcium channel blockade appears crucial for improving LV hypertrophy and diastolic function in hypertension.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...